Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: De Grève, Jacques, Van Meerbeeck, Jan, Vansteenkiste, Johan F., Decoster, Lore, Meert, Anne-Pascale, Vuylsteke, Peter, Focan, Christian, Canon, Jean-Luc, Humblet, Yves, Berchem, Guy, Colinet, Benoit, Galdermans, Danny, Bosquée, Lionel, Vermeij, Joanna, Dewaele, Alex, Geers, Caroline, Schallier, Denis, Teugels, Erik
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4816447/
https://ncbi.nlm.nih.gov/pubmed/27032107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0147599
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados